The publication of University of Health Sciences Istanbul Sisli Hamidiye Etfal Application and Research Center.


Online article submission system has been turned over to eJManager. We kindly request you to submit your current article or new articles via eJManager system

          VOLUME 37 / ISSUE 1


The Journal is Indexed in


4 - Comparison of chemotherapy protocols in NSCLC

Ö. Maral, D. Karaçetin, B. Yücel, Ö. Aksakal, D. Özcan, Y. Başer, O. İncekara

Objective: In spite of surgery, chemotherapy and radiotherapy, median survival in NSCLC is about 8 to 10 months. Thus alternative regimens are heeing tried. In this study we aimed to evaluated different chemotherapy regimens to their effectivies and tolerability.

Study design: The years of 1996-1999, 235 NSCLC patients who we are treated and followed up more than 6 months in Sisli Etfal Hospital, Radiation Oncology clinic are evaluated.

Results: The patients are compared, for the time to progression, Survival and side effects. 62 patients were received ICE, 67 patients were received cisplatinum and etoposide, 98 patients were received cisplatinum+vinorelbine+gemcitabine and 8 patients were received oral etoposide in 6 cycles. Chemotherapy was given after surgery and/or radiotheray. The time during the followed up métastasés were seen; 13 patients in ICE arm, 15 patients in cisplatinum+etoposide arm and. 21 patients in cisplatinum+vinorelbine+gemcitabine arm. Exitus was seen 41 patients in ICE arm, 36 patients in Cisplatinum+etoposide arm, 64 patients in cisplatinum+vinorelhine+gemcitabine arm and 4 patients in oral etoposide arm. The time to progression was 4.5 months in ICE arm, 4.1 months in cisplatinum+etoposide arm, 4 months in cisplatinum+vinorelbine+gemcitabine arm. Median survival was 11.1 months in ICE are, 12.2 months in cisplatinum+etoposide arm, 13.6 months in cisplatinum+vinorelbine+gemcitabine arm. (p: 0.11) There was not seen any toxicides WHO grade 3-4. There was no any patients who died during the chemotherapy arm, 36 patients in ci.splat.inum+etoposide arm, 64 patients in cisplatinum+vinorelbine+gemcitabine arm and 4 patients in oral etoposide. The time to progression was 4.5 months in ICE arm, 4.1 months in cisp- latinum+etoposide arm, 4 months in cisplatinum+vinorelbine+gemcitabine arm. Median survival was 11.1 months in ICE are, 12.2 months in cisplatinum+etoposide arm, 13.6 months in cisplatinum+vinorelbine+gemcitahine arm. (p: O.llJThere was not seen any toxicides WHO grade 3-4. There was no any patients who died during the chemotherapy.

Conclusion: Cisplatinum+vinorelbine+gemcitabine regimens is well tolerated. It has equavalent effectivines when compared the other standart regimens.

Keywords:

To read full article click


Home Page       Editorial       Editorial Board       Advisory Board       Information for Authors       Contact       Archive

Copyright ® 2011 Sisli Etfal Hastanesi Tıp Bülteni